Urapidil in hypercholesterolemic hypertensive patients

L. A. Ferrara, G. Leonetti, R. Fogari, C. Mazzola, M. Mancini, A. Zanchetti

Research output: Contribution to journalArticle

Abstract

The association of arterial hypertension and hyperlipidemia strikingly enhances prevalence, incidence and mortality of cardiovascular disease. In the light of recent evidence that some antihypertensive drugs with α-1 blocking properties reduce blood pressure (BP) and total cholesterol (chol), increasing chol content in the non-atherogenic high density lipoproteins (HDL-chol), the effects of urapidil, a peripheral α-1 adrenoceptor antagonist, with a central action component on BP and plasma lipids were evaluated in 49 mild, hypertensive patients with mild to moderately severe hypercholesterolemia (serum chol 220-320 mg/dl) for a 6 month period in a double blind randomized study versus placebo. Five out of the 49 patients (3 on urapidil, 2 on placebo) discontinued treatment due to adverse side effects. Five patients on placebo did not meet protocol requirement of serum triglycerides <350 mg/dl (3.95 mmol/L) and were only included in the BP efficacy assessment. The groups of urapidil and placebo were comparable for age (50 ± 10 vs 49 ± 7 years), body weight (72 ± 9 vs 73 ± 10 kg), sex (18M, 8F vs 14M, 9F) and mean arterial pressure (119.4 ± 4 vs 119.7 ± 4 mmHg). The actively treated group significantly decreased BP values from 159/99 ± 13/2 to 152/90 ± 23/8 mmHg, whilst no change was observed in the placebo group. Between group analysis showed a significant difference at the end of treatment (p <0.05). Total serum chol showed a trend toward a decrease (from 265 ± 42 to 260 ± 36 mg/dl) in the patients treated with urapidil, while patients on placebo had a non-significant increase from 256 ± 29 to 261 ± 23 mg/dl. LDL-chol and apolipoprotein B-100 also showed a slight decrease in the urapidil patients and slight increase in the placebo patients. HDL-chol remained unchanged in both groups; apolipoprotein A slightly increased in the urapidil group. These results indicate that in the high risk patients with hypertension and hypercholesterolemia, urapidil favorably affects the risk profile reducing BP and producing a trend towards improvement of lipid variables. These data are supported by the results of several recent clinical trials that show the beneficial effects of urapidil on plasma lipid profile.

Original languageEnglish
Pages (from-to)39-44
Number of pages6
JournalBlood Pressure, Supplement
Volume3
Issue number4
Publication statusPublished - 1994

Fingerprint

Placebos
Blood Pressure
Cholesterol
HDL Cholesterol
Hypercholesterolemia
Lipids
Serum
Apolipoproteins A
Apolipoprotein B-100
Hypertension
urapidil
Hyperlipidemias
Double-Blind Method
LDL Cholesterol
Adrenergic Receptors
Antihypertensive Agents
Arterial Pressure
Triglycerides
Cardiovascular Diseases
Body Weight

Keywords

  • hypercholesterolemia
  • hypertension
  • placebo
  • risk factors
  • serum lipids
  • urapidil

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine

Cite this

Ferrara, L. A., Leonetti, G., Fogari, R., Mazzola, C., Mancini, M., & Zanchetti, A. (1994). Urapidil in hypercholesterolemic hypertensive patients. Blood Pressure, Supplement, 3(4), 39-44.

Urapidil in hypercholesterolemic hypertensive patients. / Ferrara, L. A.; Leonetti, G.; Fogari, R.; Mazzola, C.; Mancini, M.; Zanchetti, A.

In: Blood Pressure, Supplement, Vol. 3, No. 4, 1994, p. 39-44.

Research output: Contribution to journalArticle

Ferrara, LA, Leonetti, G, Fogari, R, Mazzola, C, Mancini, M & Zanchetti, A 1994, 'Urapidil in hypercholesterolemic hypertensive patients', Blood Pressure, Supplement, vol. 3, no. 4, pp. 39-44.
Ferrara LA, Leonetti G, Fogari R, Mazzola C, Mancini M, Zanchetti A. Urapidil in hypercholesterolemic hypertensive patients. Blood Pressure, Supplement. 1994;3(4):39-44.
Ferrara, L. A. ; Leonetti, G. ; Fogari, R. ; Mazzola, C. ; Mancini, M. ; Zanchetti, A. / Urapidil in hypercholesterolemic hypertensive patients. In: Blood Pressure, Supplement. 1994 ; Vol. 3, No. 4. pp. 39-44.
@article{c415bf62eb6b42aeb02ed18b489b45a3,
title = "Urapidil in hypercholesterolemic hypertensive patients",
abstract = "The association of arterial hypertension and hyperlipidemia strikingly enhances prevalence, incidence and mortality of cardiovascular disease. In the light of recent evidence that some antihypertensive drugs with α-1 blocking properties reduce blood pressure (BP) and total cholesterol (chol), increasing chol content in the non-atherogenic high density lipoproteins (HDL-chol), the effects of urapidil, a peripheral α-1 adrenoceptor antagonist, with a central action component on BP and plasma lipids were evaluated in 49 mild, hypertensive patients with mild to moderately severe hypercholesterolemia (serum chol 220-320 mg/dl) for a 6 month period in a double blind randomized study versus placebo. Five out of the 49 patients (3 on urapidil, 2 on placebo) discontinued treatment due to adverse side effects. Five patients on placebo did not meet protocol requirement of serum triglycerides <350 mg/dl (3.95 mmol/L) and were only included in the BP efficacy assessment. The groups of urapidil and placebo were comparable for age (50 ± 10 vs 49 ± 7 years), body weight (72 ± 9 vs 73 ± 10 kg), sex (18M, 8F vs 14M, 9F) and mean arterial pressure (119.4 ± 4 vs 119.7 ± 4 mmHg). The actively treated group significantly decreased BP values from 159/99 ± 13/2 to 152/90 ± 23/8 mmHg, whilst no change was observed in the placebo group. Between group analysis showed a significant difference at the end of treatment (p <0.05). Total serum chol showed a trend toward a decrease (from 265 ± 42 to 260 ± 36 mg/dl) in the patients treated with urapidil, while patients on placebo had a non-significant increase from 256 ± 29 to 261 ± 23 mg/dl. LDL-chol and apolipoprotein B-100 also showed a slight decrease in the urapidil patients and slight increase in the placebo patients. HDL-chol remained unchanged in both groups; apolipoprotein A slightly increased in the urapidil group. These results indicate that in the high risk patients with hypertension and hypercholesterolemia, urapidil favorably affects the risk profile reducing BP and producing a trend towards improvement of lipid variables. These data are supported by the results of several recent clinical trials that show the beneficial effects of urapidil on plasma lipid profile.",
keywords = "hypercholesterolemia, hypertension, placebo, risk factors, serum lipids, urapidil",
author = "Ferrara, {L. A.} and G. Leonetti and R. Fogari and C. Mazzola and M. Mancini and A. Zanchetti",
year = "1994",
language = "English",
volume = "3",
pages = "39--44",
journal = "Blood Pressure, Supplement",
issn = "0803-8023",
publisher = "Taylor and Francis Ltd.",
number = "4",

}

TY - JOUR

T1 - Urapidil in hypercholesterolemic hypertensive patients

AU - Ferrara, L. A.

AU - Leonetti, G.

AU - Fogari, R.

AU - Mazzola, C.

AU - Mancini, M.

AU - Zanchetti, A.

PY - 1994

Y1 - 1994

N2 - The association of arterial hypertension and hyperlipidemia strikingly enhances prevalence, incidence and mortality of cardiovascular disease. In the light of recent evidence that some antihypertensive drugs with α-1 blocking properties reduce blood pressure (BP) and total cholesterol (chol), increasing chol content in the non-atherogenic high density lipoproteins (HDL-chol), the effects of urapidil, a peripheral α-1 adrenoceptor antagonist, with a central action component on BP and plasma lipids were evaluated in 49 mild, hypertensive patients with mild to moderately severe hypercholesterolemia (serum chol 220-320 mg/dl) for a 6 month period in a double blind randomized study versus placebo. Five out of the 49 patients (3 on urapidil, 2 on placebo) discontinued treatment due to adverse side effects. Five patients on placebo did not meet protocol requirement of serum triglycerides <350 mg/dl (3.95 mmol/L) and were only included in the BP efficacy assessment. The groups of urapidil and placebo were comparable for age (50 ± 10 vs 49 ± 7 years), body weight (72 ± 9 vs 73 ± 10 kg), sex (18M, 8F vs 14M, 9F) and mean arterial pressure (119.4 ± 4 vs 119.7 ± 4 mmHg). The actively treated group significantly decreased BP values from 159/99 ± 13/2 to 152/90 ± 23/8 mmHg, whilst no change was observed in the placebo group. Between group analysis showed a significant difference at the end of treatment (p <0.05). Total serum chol showed a trend toward a decrease (from 265 ± 42 to 260 ± 36 mg/dl) in the patients treated with urapidil, while patients on placebo had a non-significant increase from 256 ± 29 to 261 ± 23 mg/dl. LDL-chol and apolipoprotein B-100 also showed a slight decrease in the urapidil patients and slight increase in the placebo patients. HDL-chol remained unchanged in both groups; apolipoprotein A slightly increased in the urapidil group. These results indicate that in the high risk patients with hypertension and hypercholesterolemia, urapidil favorably affects the risk profile reducing BP and producing a trend towards improvement of lipid variables. These data are supported by the results of several recent clinical trials that show the beneficial effects of urapidil on plasma lipid profile.

AB - The association of arterial hypertension and hyperlipidemia strikingly enhances prevalence, incidence and mortality of cardiovascular disease. In the light of recent evidence that some antihypertensive drugs with α-1 blocking properties reduce blood pressure (BP) and total cholesterol (chol), increasing chol content in the non-atherogenic high density lipoproteins (HDL-chol), the effects of urapidil, a peripheral α-1 adrenoceptor antagonist, with a central action component on BP and plasma lipids were evaluated in 49 mild, hypertensive patients with mild to moderately severe hypercholesterolemia (serum chol 220-320 mg/dl) for a 6 month period in a double blind randomized study versus placebo. Five out of the 49 patients (3 on urapidil, 2 on placebo) discontinued treatment due to adverse side effects. Five patients on placebo did not meet protocol requirement of serum triglycerides <350 mg/dl (3.95 mmol/L) and were only included in the BP efficacy assessment. The groups of urapidil and placebo were comparable for age (50 ± 10 vs 49 ± 7 years), body weight (72 ± 9 vs 73 ± 10 kg), sex (18M, 8F vs 14M, 9F) and mean arterial pressure (119.4 ± 4 vs 119.7 ± 4 mmHg). The actively treated group significantly decreased BP values from 159/99 ± 13/2 to 152/90 ± 23/8 mmHg, whilst no change was observed in the placebo group. Between group analysis showed a significant difference at the end of treatment (p <0.05). Total serum chol showed a trend toward a decrease (from 265 ± 42 to 260 ± 36 mg/dl) in the patients treated with urapidil, while patients on placebo had a non-significant increase from 256 ± 29 to 261 ± 23 mg/dl. LDL-chol and apolipoprotein B-100 also showed a slight decrease in the urapidil patients and slight increase in the placebo patients. HDL-chol remained unchanged in both groups; apolipoprotein A slightly increased in the urapidil group. These results indicate that in the high risk patients with hypertension and hypercholesterolemia, urapidil favorably affects the risk profile reducing BP and producing a trend towards improvement of lipid variables. These data are supported by the results of several recent clinical trials that show the beneficial effects of urapidil on plasma lipid profile.

KW - hypercholesterolemia

KW - hypertension

KW - placebo

KW - risk factors

KW - serum lipids

KW - urapidil

UR - http://www.scopus.com/inward/record.url?scp=0028711248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028711248&partnerID=8YFLogxK

M3 - Article

C2 - 7804511

AN - SCOPUS:0028711248

VL - 3

SP - 39

EP - 44

JO - Blood Pressure, Supplement

JF - Blood Pressure, Supplement

SN - 0803-8023

IS - 4

ER -